gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PROFHealthcareSurgical Instruments

Profound Medical Corp. Common Stock (PROF)

$7.16+2.43%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$6.99▲ 17.28% in range
Nov 3, 2025Low $5.06 · High $8.65Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Profound Medical closed at $7.16 on Nov 4, up 2.43%, 17.2% below its 52-week closing high. Volume of 427.1K shares was 1.19× its 20-day average (close to normal).

Split-adjusted performance: +17.8% over one month, -0.8% over six months, +20.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $2.48M, up 12.3% from a year earlier, with a net margin of -384.2%.

Short interest was 1.6M shares at the Oct 15 settlement, up 5.0% from the prior report (4.3% of float, 3.2 days to cover).

Market cap$261.6M36.5M shares
Revenue · quarter$2.5M+12.3% YoY
Diluted EPS$-0.26—
P/E · TTM—P/S 13.7×
Net margin-384.2%Gross 78.4%
Dividend yieldNone
52-week range5.06 – 8.65−17.2% from high
Volume427.1K1.19× 20-day avg
Volatility · 60d69.9%Annualised
Short % of float4.3%3.2 days to cover
Net cash$33.8MCash $38.3M
Next earnings—Not scheduled
Split-adjusted performance
1W +23.9%1M +17.8%3M −9.8%6M −0.8%YTD −9.0%1Y +20.1%3Y −11.6%5Y −46.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum52
Revenue growth56
Net margin13
Value (low P/E)—
Size47

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short1.6M+5.0% vs prior
Days to cover3.2Settled Oct 15
% of float4.3%
Short vol. 10d69.8%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PROFProfound Medical$7.16+2.43%−0.8%+12.3%−384.2%—$261.6M
INFUInfuSystem Holdings$13.15+2.73%+29.7%+2.6%8.7%30.7$261.9MCompare
OSUROraSure Technologies$3.72+5.38%+24.0%−1.9%20.4%—$256.6MCompare
ANIKAnika Therapeutics$20.40+4.88%+34.9%+15.6%10.1%—$273.0MCompare
TLSITriSalus Life Sciences$3.89+11.78%−14.5%+1.7%−80.5%—$239.5MCompare
TMCITreace Medical Concepts$4.50+5.14%+133.2%−4.2%−35.0%—$292.7MCompare
UTMDUtah Medical Products$72.42+3.43%+12.4%−14.3%31.5%21.9$229.9MCompare
CLPTClearPoint Neuro$10.16+4.63%−11.4%+36.3%−61.8%—$325.7MCompare
NEGGNewegg Commerce$9.89+7.62%−68.9%———$207.4MCompare

News about Profound Medical

All news →
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to TradeZacks Investment Research · 5d ago▲ PositiveDoes Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?Zacks Investment Research · Oct 14, 2026▲ PositiveStrength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?Zacks Investment Research · Oct 9, 2026▲ PositiveProfound Medical Corp. Investigated by the Portnoy Law FirmGlobeNewswire Inc. · Apr 9, 2026▼ Negative

Quick answers

What does Profound Medical do?
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.
What is PROF's market cap?
$261.63M, based on the Nov 4 close of $7.16.
Does Profound Medical pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PROF is sold short?
1.6M shares, 4.3% of float, as of Oct 15, 2026.
What sector is PROF in?
Healthcare, in the Surgical Instruments industry.

About Profound Medical

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

HQ: Mississauga, A6162 employeesListed May 9, 2016profoundmedical.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology